



## hereditary angioedema

Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting. Swelling in the airway can restrict breathing and lead to life-threatening obstruction of the airway. About one-third of people with this condition develop a non-itchy rash called erythema marginatum during an attack.

Symptoms of hereditary angioedema typically begin in childhood and worsen during puberty. On average, untreated individuals have an attack every 1 to 2 weeks, and most episodes last for about 3 to 4 days. The frequency and duration of attacks vary greatly among people with hereditary angioedema, even among people in the same family.

There are three types of hereditary angioedema, called types I, II, and III, which can be distinguished by their underlying causes and levels of a protein called C1 inhibitor in the blood. The different types have similar signs and symptoms. Type III was originally thought to occur only in women, but families with affected males have been identified.

### Frequency

Hereditary angioedema is estimated to affect 1 in 50,000 people. Type I is the most common, accounting for 85 percent of cases. Type II occurs in 15 percent of cases, and type III is very rare.

### Genetic Changes

Mutations in the *SERPING1* gene cause hereditary angioedema type I and type II. The *SERPING1* gene provides instructions for making the C1 inhibitor protein, which is important for controlling inflammation. C1 inhibitor blocks the activity of certain proteins that promote inflammation. Mutations that cause hereditary angioedema type I lead to reduced levels of C1 inhibitor in the blood, while mutations that cause type II result in the production of a C1 inhibitor that functions abnormally. Without the proper levels of functional C1 inhibitor, excessive amounts of a protein fragment (peptide) called bradykinin are generated. Bradykinin promotes inflammation by increasing the leakage of fluid through the walls of blood vessels into body tissues. Excessive accumulation of fluids in body tissues causes the episodes of swelling seen in individuals with hereditary angioedema type I and type II.

Mutations in the *F12* gene are associated with some cases of hereditary angioedema type III. This gene provides instructions for making a protein called coagulation factor XII. In addition to playing a critical role in blood clotting (coagulation), factor XII is also an important stimulator of inflammation and is involved in the production of bradykinin. Certain mutations in the *F12* gene result in the production of factor XII with increased activity. As a result, more bradykinin is generated and blood vessel walls become more leaky, which leads to episodes of swelling in people with hereditary angioedema type III.

The cause of other cases of hereditary angioedema type III remains unknown. Mutations in one or more as-yet unidentified genes may be responsible for the disorder in these cases.

### **Inheritance Pattern**

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

In some cases, an affected person inherits the mutation from one affected parent. Other cases result from new mutations in the gene and occur in people with no history of the disorder in their family.

### **Other Names for This Condition**

- C1 esterase inhibitor deficiency
- C1 inhibitor deficiency
- HAE
- HANE
- hereditary angioneurotic edema

### **Diagnosis & Management**

#### Genetic Testing

- Genetic Testing Registry: Hereditary angioneurotic edema  
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0019243/>
- Genetic Testing Registry: Hereditary angioneurotic edema with normal C1 esterase inhibitor activity  
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C1857728/>
- Genetic Testing Registry: Hereditary C1 esterase inhibitor deficiency - dysfunctional factor  
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C1862892/>

### Other Diagnosis and Management Resources

- MedlinePlus Encyclopedia: Hereditary angioedema  
<https://medlineplus.gov/ency/article/001456.htm>
- National Organization for Rare Disorders (NORD) Physician Guide  
<http://nordphysicianguides.org/hereditary-angioedema/>

### General Information from MedlinePlus

- Diagnostic Tests  
<https://medlineplus.gov/diagnostictests.html>
- Drug Therapy  
<https://medlineplus.gov/drugtherapy.html>
- Genetic Counseling  
<https://medlineplus.gov/geneticcounseling.html>
- Palliative Care  
<https://medlineplus.gov/palliativecare.html>
- Surgery and Rehabilitation  
<https://medlineplus.gov/surgeryandrehabilitation.html>

## **Additional Information & Resources**

### MedlinePlus

- Encyclopedia: Hereditary angioedema  
<https://medlineplus.gov/ency/article/001456.htm>
- Health Topic: Vascular Diseases  
<https://medlineplus.gov/vascular diseases.html>

### Genetic and Rare Diseases Information Center

- Hereditary angioedema  
<https://rarediseases.info.nih.gov/diseases/5979/hereditary-angioedema>

### Educational Resources

- Disease InfoSearch: Hereditary angioedema  
<http://www.diseaseinfosearch.org/Hereditary+angioedema/3342>
- MalaCards: hereditary angioedema  
[http://www.malacards.org/card/hereditary\\_angioedema](http://www.malacards.org/card/hereditary_angioedema)

- Merck Manual Professional Version  
<http://www.merckmanuals.com/professional/immunology-allergic-disorders/allergic,-autoimmune,-and-other-hypersensitivity-disorders/hereditary-and-acquired-angioedema>
- Orphanet: Hereditary angioedema  
[http://www.orpha.net/consor/cgi-bin/OC\\_Exp.php?Lng=EN&Expert=91378](http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=91378)

#### Patient Support and Advocacy Resources

- International Patient Organization for C1 Inhibitor Deficiencies  
<http://haei.org/>
- National Organization for Rare Disorders (NORD)  
<https://rarediseases.org/rare-diseases/hereditary-angioedema/>

#### ClinicalTrials.gov

- ClinicalTrials.gov  
<https://clinicaltrials.gov/ct2/results?cond=%22hereditary+angioedema%22>

#### Scientific Articles on PubMed

- PubMed  
<https://www.ncbi.nlm.nih.gov/pubmed?term=%28Angioneurotic+Edema%5BMAJR%5D%29+AND+%28%28hereditary+angioedema%5BTIAB%5D%29+OR+%28hae%5BTIAB%5D%29+OR+%28hereditary+angioneurotic+edema%5BTIAB%5D%29+OR+%28c1+esterase+inhibitor+deficiency%5BTIAB%5D%29+OR+%28c1+inhibitor+deficiency%5BTIAB%5D%29+OR+%28hane%5BTIAB%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+360+days%22%5Bdp%5D>

#### OMIM

- ANGIOEDEMA, HEREDITARY, TYPE I  
<http://omim.org/entry/106100>
- ANGIOEDEMA, HEREDITARY, TYPE III  
<http://omim.org/entry/610618>

#### **Sources for This Summary**

- OMIM: ANGIOEDEMA, HEREDITARY, TYPE I  
<http://omim.org/entry/106100>
- OMIM: ANGIOEDEMA, HEREDITARY, TYPE III  
<http://omim.org/entry/610618>

- Cichon S, Martin L, Hennies HC, Müller F, Van Driessche K, Karpushova A, Stevens W, Colombo R, Renné T, Drouet C, Bork K, Nöthen MM. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. *Am J Hum Genet*. 2006 Dec;79(6):1098-104. Epub 2006 Oct 18.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/17186468>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698720/>
- Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. *Trends Mol Med*. 2009 Feb;15(2):69-78. doi: 10.1016/j.molmed.2008.12.001. Epub 2009 Jan 21. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/19162547>
- Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. *Biochem Biophys Res Commun*. 2006 May 19; 343(4):1286-9.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/16638441>
- Gösswein T, Kocot A, Emmert G, Kreuz W, Martinez-Saguer I, Aygören-Pürsün E, Rusicke E, Bork K, Oldenburg J, Müller CR. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. *Cytogenet Genome Res*. 2008;121(3-4):181-8. doi: 10.1159/000138883. Epub 2008 Aug 28.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/18758157>
- Krishnamurthy A, Naguwa SM, Gershwin ME. Pediatric angioedema. *Clin Rev Allergy Immunol*. 2008 Apr;34(2):250-9. doi: 10.1007/s12016-007-8037-y. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/18330729>
- Martin L, Raison-Peyron N, Nöthen MM, Cichon S, Drouet C. Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. *J Allergy Clin Immunol*. 2007 Oct;120(4):975-7. Epub 2007 Sep 7.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/17825897>
- Pappalardo E, Caccia S, Suffritti C, Tordai A, Zingale LC, Cicardi M. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. *Mol Immunol*. 2008 Aug;45(13):3536-44. doi: 10.1016/j.molimm.2008.05.007. Epub 2008 Jun 30.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/18586324>
- Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S. C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. *Expert Opin Biol Ther*. 2008 Aug;8(8):1225-40. doi: 10.1517/14712598.8.8.1225. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/18613773>
- Zuraw BL. Clinical practice. Hereditary angioedema. *N Engl J Med*. 2008 Sep 4;359(10):1027-36. doi: 10.1056/NEJMcp0803977. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/18768946>

---

Reprinted from Genetics Home Reference:

<https://ghr.nlm.nih.gov/condition/hereditary-angioedema>

Reviewed: April 2009

Published: March 21, 2017

Lister Hill National Center for Biomedical Communications  
U.S. National Library of Medicine  
National Institutes of Health  
Department of Health & Human Services